This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Dutch-Belgian Lung Cancer Screening trial (NELSON)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Lung cancer is the leading cause of cancer death worldwide - this is mainly due to its advanced stage at the time of diagnosis

  • the results of the National Lung Screening Trial (NLST), the US Preventive Services Task Force recommends annual lung cancer screening with CT
    • eligibility for screening
      • aged 55 years through 80 years, have smoked at least 30 pack-years, and currently smoke or have quit within the past 15 years

  • the Dutch-Belgian Lung Cancer Screening trial (NELSON) is the largest European randomised lung cancer screening trial, which was designed to investigate whether (low-dose CT) LDCT screening reduces lung cancer mortality by >=25% compared with no screening after 10 years of follow-up
    • study participants were individuals aged 50-74 years in the Netherlands and Leuven, Belgium, who were considered at high risk for lung cancer based on responses to a general questionnaire
    • participants' records were linked with national registries with 100% coverage regarding cancer diagnosis and date and cause of death, and medical records for deceased lung cancer patients were reviewed by a blinded expert panel through 2013, and for the remaining study years cause of death as reported by Statistics Netherlands was used
    • participants were randomized to CT screening at baseline, 1, 3, and 5.5 years after randomization, or to a control group that received usual care
      • overall 157 lung cancer deaths occurred in the screening arm vs. 250 in the control arm.
      • detection rates varied between 0.8% and 1.1% across screenings (0.9% overall), and the positive predictive value of screening was 41%
      • stage at diagnosis:
        • 69% of the 243 lung cancers detected by screening were detected at stage 1A or 1B, compared with 10%-12% being detected at stage 4 in about 50% of control patient
    • CT screening reduced the risk of death from lung cancer with an overall reduction of 26% at 10 years

Analyses of the first three rounds of the NELSON trial indicated that a 2-year interval between the second and the third screening rounds did not lead to a significantly higher proportion of advanced stage lung cancers compared with a 1-year screening interval between the first and second rounds

  • An interval of 2.5 years leads to a higher interval cancer rate and a higher proportion of advanced stage disease in the final fourth round compared with the previous screening rounds with a 1-year or 2-year screening interval
    • a 2.5-year interval reduced the effect of screening: the interval cancer rate was higher compared with the 1-year and 2-year intervals, and proportion of advanced disease stage in the final round was higher compared with the previous rounds


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page